Vitamin D supplementation for chronic liver diseases in adults
CONCLUSIONS: Given the high risk of bias and insufficient power of the included trials and the very low certainty of the available evidence, vitamin D supplementation versus placebo or no intervention may increase or reduce all-cause mortality, liver-related mortality, serious adverse events, or non-serious adverse events in adults with chronic liver diseases. There is a lack of data on liver-related morbidity and health-related quality of life. Further evidence on clinically important outcomes analysed in this review is needed.PMID:34431511 | DOI:10.1002/14651858.CD011564.pub3
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Milica Bjelakovic Dimitrinka Nikolova Goran Bjelakovic Christian Gluud Source Type: research
More News: Alcoholism | Bleeding | Cancer | Cancer & Oncology | Cirrhosis | Clinical Trials | Conferences | Databases & Libraries | Fatty Liver Disease (FLD) | Gastroenterology | General Medicine | Heart Attack | Hepatitis | Hepatitis C | Hypercalcaemia | International Medicine & Public Health | Liver | Liver Disease | Liver Transplant | Non-alcoholic Fatty Liver Diseases (NAFLD) | PET Scan | Science | Thyroiditis | Transplant Surgery | Transplants | Urology & Nephrology | Virology | Vitamin D | Vitamin D Deficiency | Vitamin D2 | Vitamin D3 | Vitamins | WHO | Women